These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 16855176

  • 1. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J, Gödde A, Schütz E, Bongartz TA, Lang B, Schölmerich J, Müller-Ladner U.
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 4. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 5. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB, Barclay ML.
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.
    Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis.
    Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, van de Putte LB.
    Arthritis Rheum; 1998 Oct; 41(10):1858-66. PubMed ID: 9778228
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J.
    Aliment Pharmacol Ther; 2008 Oct 15; 28(8):973-83. PubMed ID: 18616518
    [Abstract] [Full Text] [Related]

  • 12. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q, Zhu Q, Shang Y, Gao M, Si J.
    Digestion; 2009 Oct 15; 79(1):58-63. PubMed ID: 19252404
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
    Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM.
    Clin Gastroenterol Hepatol; 2004 May 15; 2(5):410-7. PubMed ID: 15118980
    [Abstract] [Full Text] [Related]

  • 16. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S, Vikingsson S, Söderman J, Hindorf U, Grännö C, Danelius M, Coulthard S, Peterson C, Almer S.
    Ther Drug Monit; 2011 Apr 15; 33(2):200-8. PubMed ID: 21311411
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.
    Scand J Gastroenterol; 2004 Nov 15; 39(11):1105-12. PubMed ID: 15545169
    [Abstract] [Full Text] [Related]

  • 19. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML.
    Clin Gastroenterol Hepatol; 2008 Jun 15; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [Abstract] [Full Text] [Related]

  • 20. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML.
    Aliment Pharmacol Ther; 2012 May 15; 35(10):1181-9. PubMed ID: 22486532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.